Teva to acquire Cephalon, topping Valeant
Teva Pharmaceutical Industries Ltd
Teva said the deal was worth about $6.8 billion on an enterprise basis. The deal is worth about $6.2 billion, based on the number of Cephalon shares outstanding, according to Thomson Reuters data.
(Reporting by Lewis Krauskopf; Editing by Lisa Von Ahn)
© Copyright Thomson Reuters 2024. All rights reserved.
Join the Discussion
Editor's pick